An interview with Damon Race discussing GeneVentiv and its gene-therapy program for hemophilia patients with inhibitors.
Rare Disease Advisor senior correspondent Larry Luxner interviewed Damon Race about GeneVentiv’s development strategy and the company’s historical goal of developing a gene therapy for hemophilia A or B patients with inhibitors.